DUBLIN, March 3, 2017 /PRNewswire/ -- Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, announced today that it will present 21 Allergan-supported abstracts, a record high for the brand, at the 2017 Annual American Academy of Dermatology (AAD) meeting in Orlando, Florida from March 3-7, 2017.
The scheduled times (noted in local Eastern Time) of the 21 Allergan presentations, presentation titles, locations and authors are as follows:
Efficacy and Safety of OnabotulinumtoxinA for Moderate to Severe Forehead Lines in Subjects With Upper Facial Lines
Efficacy and Safety of OnabotulinumtoxinA for Treatment of Moderate to Severe Forehead Lines
OnabotulinumtoxinA (BOTOX®) Displays Superior Activity to IncobotulinumtoxinA Drug Product (XEOMIN®) in Multiple In Vitro and In Vivo Assays
Safety and Tolerability of OnabotulinumtoxinA in the Treatment of Facial Lines: Statistical Meta-analysis of Pooled Data From Global Registration Studies of Treatment of Crow's Feet Lines and Glabellar Lines in More Than 3900 Participants
A comparison of self-reported signs of facial aging among women in Australia vs. those in the United States, United Kingdom & Canada
Characterization of the In Vivo Pharmacology of Oxymetazoline and Brimonidine Using a Mouse Model of UV-Induced Erythema
Efficacy and Safety of Topical Oxymetazoline Cream 1.0% for Treatment of Facial Erythema Associated With Rosacea: Findings From Two Phase 3, Pivotal Trials
Patient-Rated Satisfaction Assessment for Rosacea Facial Redness (SAT-RFR): Results of Two Phase 3 Pivotal Trials of Oxymetazoline Cream 1% vs Vehicle
Patient-Rated Symptom Assessment for Rosacea Facial Redness (SA-RFR): Results of Two Phase 3 Pivotal Trials of Oxymetazoline Cream 1% vs Vehicle
Development and Validation of the Satisfaction Assessment for Rosacea Facial Redness (SAT-RFR)
Development and Validation of the Symptom Assessment for Rosacea Facial Redness (SA-RFR)
Efficacy and Safety of Topical Oxymetazoline Cream 1.0% for the Treatment of Facial Erythema Associated With Rosacea: Findings From 1 of 2 Pivotal Trials
Efficacy and Safety of Topical Oxymetazoline Cream 1.0% for the Treatment of Facial Erythema Associated With Rosacea: Findings From the Second of 2 Pivotal Trials
Long-term Safety and Efficacy of Topical Oxymetazoline Cream 1.0% for Treatment of Persistent Facial Erythema Associated With Rosacea
Efficacy and Safety of Oral Sarecycline for the Treatment of Moderate to Severe Facial Acne Vulgaris: Results of a Phase 2, Dose-Ranging Trial
Cosmetic Efficacy of a Comprehensive Serum for Facial Hyperpigmentation in Multiple Ethnic Populations
Efficacy of a Comprehensive Serum in Japanese Subjects with Moderate to Severe Facial Hyperpigmentation
Efficacy of a Comprehensive Serum in Thai Subjects with Moderate to Severe Facial Hyperpigmentation
Rejuvenation in neck appearance from topical treatment with physiologically-balanced growth factors, antioxidants and sunscreen actives
Social Perceptions Before and After Treatment With ATX-101 (Deoxycholic Acid Injection) for Reduction of Submental Fat
Pan-facial Aesthetic Treatment Positively and Significantly Impacts Social Perception
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, the Company's R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.
Our Company's success is powered by our more than 16,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
For more information, visit Allergan's website at www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 (certain of such periodic public filings having been filed under the "Actavis plc" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
© 2017 Allergan. All rights reserved. All trademarks are the property of their respective owners.
CONTACTS:
Investors:
Lisa DeFrancesco
(862) 261-7152
Karina Calzadilla
(862) 261-7328
Media:
Mark Marmur
(862) 261-7558
Ember Garrett
(714) 246-3525
SOURCE Allergan plc